

LIPPINCOTT  
WILLIAMS &  
WILKINS



SPIRAL<sup>®</sup>  
MANUAL

(英文原版)


# Manual of Clinical Hematology

Third Edition

配英汉索引

# 临床血液学手册

Edited by  
Joseph J. Mazza



Lippincott Williams & Wilkins Inc. 授权

天津科技翻译出版公司出版

LIPPINCOTT  
WILLIAMS &  
WILKINS



SPIRAL<sup>®</sup>  
MANUAL

(英文原版)

# Manual of Clinical Hematology


Third Edition

配英汉索引

# 临床血液学手册

Edited by

Joseph J. Mazza



Lippincott Williams & Wilkins Inc. 授权  
天津科技翻译出版公司出版

著作权合同登记号:图字:02-2002-101

---

**图书在版编目(CIP)数据**

临床血液学手册 = Manual of Clinical Hematology / (美) 马扎 (Mazza, J. J.) 编著.  
影印本. - 天津: 天津科技翻译出版公司, 2003. 1

(SPIRAL<sup>®</sup> MANUAL 系列丛书)

ISBN 7-5433-1564-5

I. 临... II. 马... III. 血液病-诊疗-手册-英文 IV. R552-62

中国版本图书馆 CIP 数据核字 (2002) 第 073095 号

---

Copyright © 2002 by Lippincott Williams & Wilkins Inc.

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

Reprint authorized by Lippincott Williams & Wilkins Inc. Reprint is authorized for sale in the People's Republic of China only.

授权单位: Lippincott Williams & Wilkins Inc.

出 版: 天津科技翻译出版公司

出 版 人: 邢淑琴

地 址: 天津市南开区白堤路 244 号

邮政编码: 300192

电 话: 022-87893561

传 真: 022-87892476

E - mail: tsttbc@public.tpt.tj.cn

印 刷: 天津市蓟县宏图印务有限公司印刷

发 行: 全国新华书店

版本记录: 900×1168 32 开本 15.75 印张 500 千字

2003 年 1 月第 1 版 2003 年 1 月第 1 次印刷

定价: 39.00 元

(如发现印装问题, 可与出版社调换)

# Manual of Clinical Hematology

Third Edition

Edited by

**Joseph J. Mazza, M.D.**

Senior Consultant, Department of Hematology/Oncology,  
Marshfield Clinic, Marshfield;

Professor of Clinical Medicine, Department of Medicine,  
University of Wisconsin School of Medicine,  
Madison, Wisconsin



LIPPINCOTT WILLIAMS & WILKINS

A Wolters Kluwer Company

Philadelphia • Baltimore • New York • London  
Buenos Aires • Hong Kong • Sydney • Tokyo

*Acquisitions Editor:* Jonathan W. Pine, Jr.  
*Developmental Editor:* Stacey L. Baze  
*Production Editor:* Melanie Bennitt  
*Manufacturing Manager:* Benjamin Rivera  
*Cover Designer:* Christine Jenny  
*Compositor:* Circle Graphics  
*Printer:* R. R. Donnelley—Crawfordsville

© 2002 by LIPPINCOTT WILLIAMS & WILKINS  
530 Walnut Street  
Philadelphia, PA 19106 USA  
LWW.com

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner, except for brief quotations embodied in critical articles and reviews. Materials appearing in this book prepared by individuals as part of their official duties as U.S. government employees are not covered by the above-mentioned copyright.

Printed in the USA  
First Edition 1988  
Second Edition 1995

---

#### Library of Congress Cataloging-in-Publication Data

Manual of clinical hematology / edited by Joseph J. Mazza.—3rd ed.

p. ; cm. — (Spiral manual)

Includes bibliographical references and index.

ISBN 0-7817-2980-7

1. Blood—Diseases—Handbooks, manuals, etc. 2. Hematology—Handbooks, manuals, etc. I. Mazza, Joseph J. II. Series.

[DNLM: 1. Hematologic Diseases—Handbooks. WH 39 M2935 2002]

RC636 .M342 2002

616.1'5—dc21

2001029916

---

Care has been taken to confirm the accuracy of the information presented and to describe generally accepted practices. However, the authors, editor, and publisher are not responsible for errors or omissions or for any consequences from application of the information in this book and make no warranty, expressed or implied, with respect to the currency, completeness, or accuracy of the contents of the publication. Application of this information in a particular situation remains the professional responsibility of the practitioner.

The authors, editor, and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accordance with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new or infrequently employed drug.

Some drugs and medical devices presented in this publication have Food and Drug Administration (FDA) clearance for limited use in restricted research settings. It is the responsibility of the health care provider to ascertain the FDA status of each drug or device planned for use in their clinical practice.

10 9 8 7 6 5 4 3 2 1

*This book is dedicated to all medical residents  
for their stimulation and their contributions to medical education.  
And to their arduous quest, unceasing dedication,  
and relentless pursuit of medical knowledge,  
which are so seldom recognized and lauded.*



---

## CONTRIBUTING AUTHORS

---

**Irit Avivi, M.D.**

*Professor of Medicine, Department of Hematology and Bone Marrow Transplantation, State of Israel—Ministry of Health, Rambam Medical Center, Haifa, Israel*

**Edward J. Benz, Jr., M.D.**

*President, Dana Farber Cancer Institute; Richard and Susan Smith Professor of Medicine, Professor of Pediatrics and Pathology, Harvard Medical School, Boston, Massachusetts*

**Virgil F. Fairbanks, M.D.**

*Consultant, Department of Medicine, Mayo Foundation Clinic, St. Mary's Hospital, and Rochester Methodist Hospital; Professor Emeritus, Departments of Internal Medicine, Laboratory Medicine, and Pathology, Mayo Medical School, Rochester, Minnesota*

**Kenneth A. Foon, M.D.**

*Professor, Department of Internal Medicine, Division of Oncology, Stanford University Medical Center, Stanford, California*

**William R. Friedenbergl, M.D., F.A.C.P.**

*Chief, Division of Hematology/Oncology, Department of Medicine, Guthrie Clinic, Robert Packer Hospital, Sayre, Pennsylvania; Clinical Professor, Department of Hematology/Oncology, State University of New York, Upstate Medical University, Syracuse, New York*

**Dennis A. Gastineau, M.D.**

*Associate Professor, Divisions of Hematopathology and Transfusion Medicine, Departments of Laboratory Medicine and Pathology, Mayo Medical School, Rochester, Minnesota*

**Leo I. Gordon, M.D.**

*Chief, Division of Hematology/Oncology, Department of Medicine, Northwestern Memorial Hospital; Abby and John Friend Professor of Cancer Research, Chief, Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Chicago, Illinois*

**Jerome L. Gottschall, M.D.**

*Professor, Department of Pathology, Medical College of Wisconsin; Vice President, Medical Services, Blood Center of Southeastern Wisconsin, Inc., Milwaukee. Wisconsin*

**John D. Hines, M.D.**

*Professor, Departments of Medicine and Oncology, Case Western Reserve University School of Medicine; Senior Attending Physician, Department of Hematology/Oncology, MetroHealth Medical Center, Cleveland, Ohio*

**William G. Hocking, M.D.**

*Hematologist/Oncologist, Department of Clinical Oncology, Marshfield Clinic, Marshfield, Wisconsin; Associate Clinical Professor, Department of Medicine, University of Wisconsin, Madison, Wisconsin*

**Neil E. Kay, M.D.**

*Professor of Medicine, University of Kentucky College of Medicine; Attending Physician, Department of Hematology/Oncology, University of Kentucky Medical Center, Lexington, Kentucky*

**Robert A. Kyle, M.D.**

*Consultant, Department of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation; Professor, Mayo Medical School, Mayo Clinic and Mayo Foundation, Rochester, Minnesota*

**Hillard M. Lazarus, M.D., F.A.C.P.**

*Professor of Medicine, Director, Blood and Marrow Transplant Program, Ireland Cancer Center, Case Western Reserve University, University Hospitals of Cleveland, Cleveland, Ohio*

**Mitchell D. Martin, M.D.**

*Senior Fellow in Hematology/Oncology, University of Utah Health Sciences Center, Salt Lake City, Utah*

**Joseph J. Mazza, M.D.**

*Senior Consultant, Department of Hematology/Oncology, Marshfield Clinic, Marshfield; Professor of Clinical Medicine, Department of Medicine, University of Wisconsin School of Medicine, Madison, Wisconsin*

**Gordon D. McLaren, M.D.**

*Consultant and Attending Physician, Department of Hematology/Oncology, VA Long Beach Healthcare System, Long Beach, California; Associate Professor, Department of Medicine, University of California at Irvine, Orange, California*

**Jay E. Menitove, M.D.**

*Executive Director and Medical Director, Community Blood Center of Greater Kansas City; Clinical Professor, Department of Internal Medicine, Kansas University School of Medicine and University of Missouri—Kansas City School of Medicine, Kansas City, Missouri*

**Kenneth B. Miller, M.D.**

*Director, Bone Marrow Transplantation, Department of Medicine, New England Medical Center; Associate Professor, Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts*

**Scott Murphy, M.D.**

*Adjunct Professor of Medicine, Department of Medicine, University of Pennsylvania; Attending Physician, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania*

**Lawrence D. Petz, M.D.**

*President and Chief Medical Officer, StemCyte, Inc., Arcadia, California; Emeritus Professor, Departments of Pathology and Laboratory Medicine, UCLA Medical Center, Los Angeles, California*

**A. Koneti Rao, M.D.**

*Professor of Medicine and Thrombosis Research, Director, Thromboembolic Diseases, Temple University School of Medicine; Attending Physician, Department of Medicine, Temple University Hospital, Philadelphia, Pennsylvania*

**George M. Rodgers, M.D., Ph.D.**

*Staff Physician, Department of Medicine, University Hospital; Professor, Divisions of Hematology and Oncology, Departments of Medicine and Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah*

**Jacob M. Rowe, M.D.**

*Director, Department of Hematology and Bone Marrow Transplantation, State of Israel—Ministry of Health, Rambam Medical Center, Haifa, Israel*



**Sandra F. Schnall, M.D.**

*Associate, Department of Hematology / Oncology, Bryn Mawr Hospital, Bryn Mawr;  
Associate, Department of Hematology, Thomas Jefferson University Hospital,  
Philadelphia, Pennsylvania*

**Ayalew Tefferi, M.D.**

*Consultant, Division of Hematology and Internal Medicine, Mayo Clinic and Mayo  
Foundation; Associate Professor, Department of Medicine, Mayo Medical School,  
Rochester, Minnesota*

**Stephan D. Thomé, M.D.**

*Fellow, Department of Hematology and Medical Oncology, Mayo Clinic; Instructor,  
Department of Internal Medicine, Mayo Graduate School of Medicine, Rochester,  
Minnesota*

---

## PREFACE

---

The reward for work well done is the opportunity to do more.

*Jonas Salk, M.D.*

The incentive to proceed with the third edition of the *Manual of Clinical Hematology* was predicated on the success of the first and second editions. Updating the new edition was a more difficult task, however, given the recent explosion of technology in molecular biology and genetics that has had a direct bearing on the specialties of hematology and immunology, and the importance of maintaining this successful concise format of the text. The update information added to the chapters and the addition of the chapter on transplantation to the text will result in a more comprehensive edition that we hope will be more helpful to the reader in his or her quest to establish a firm foundation in hematology. The added chapter on transplantation procedures in hematologic disorders is in keeping with the current aim of more aggressive approaches to the treatment of hematopoietic malignancies.

We have attempted to retain the intended focus and purpose of the book; that is, to provide a concise clinical text—aimed at students, house staff, and medical practitioners not primarily involved in hematology—that describes common hematologic disorders. This publication is not intended to be an all-inclusive hematology text, but rather an introduction to clinical hematology and a readily available source of information upon which the student and physician can build. It is my fervent wish that the book will provide sufficient motivation and excite the curious student or house staff to seek additional, more detailed information from the more comprehensive reference textbooks of hematology.

Many persons have assisted and contributed to this undertaking. I am first indebted to my colleagues in the field of hematology who have so generously contributed their time and expertise to the contents of the text. I am especially grateful to my colleagues at Marshfield Clinic for allowing me sufficient time away from my practice and supplying me with unlimited library, stenographic, and medical illustration support in reviewing and editing the manuscript. Special acknowledgment is extended to Alice Stargardt for her stenographic expertise and prompt transcription of the many manuscripts prepared for the text; to Julie Seehafer for her help and guidance in preparing the appendices; to Stacey Baze for her editorial assistance; and finally, to my wife, Ginny, for her many years of encouragement and support through all my endeavors.

*J. J. M.*

# Manual of Clinical Hematology

Third Edition

# CONTENTS 目 录

## Contributing Authors

作者 ..... ix

## Preface

前言 ..... xiii

1	Hematopoiesis and Hematopoietic Growth Factors 造血和血细胞生成因子	1
2	The Anemias 贫血 Iron-deficiency Anemia 缺铁性贫血	17
	Megaloblastic Anemia 恶性贫血	39
	Anemia of Chronic Disease 慢性病引起的贫血	54
	Aplastic Anemia 再生障碍性贫血	61
3	Primary and Secondary Erythrocytosis 原发性和继发性红细胞增多症	73
4	Hemolytic Anemia: Hereditary and Acquired 溶血性贫血: 先天性和后天性	90
5	Hereditary Hemochromatosis and Other Iron-overload Disorders 先天性血色素沉着症和其他铁负荷过重疾病	118
6	Abnormalities of Hemoglobin 血红蛋白异常	138
7	Disorders of Granulocytes: Qualitative and Quantitative 粒细胞异常: 质量和数量	155
8	Platelet Disorders: Hereditary and Acquired 血小板异常: 先天性和后天性	180
9	Myeloproliferative Diseases 骨髓增生性疾病	195
10	Myelodysplastic Syndromes 骨髓发育不良综合征	205
11	Acute Leukemias in Adults 成人急性白血病	214
12	Chronic Leukemia 慢性白血病 Chronic Lymphoid Leukemias 慢性淋巴细胞白血病	228
	Chronic Myelogenous Leukemia 慢性骨髓粒细胞白血病	239
13	Multiple Myeloma and Related Monoclonal Gammopathies 多发性骨髓瘤和相关的单克隆 $\gamma$ -球蛋白病	247
14	Benign Lymphocyte Disorders 良性淋巴细胞病	274
15	Malignant Lymphomas 恶性淋巴瘤 Hodgkin Disease	

霍奇金病	297
Non-Hodgkin Lymphomas	
非霍奇金淋巴瘤	318
Cutaneous T-Cell Lymphomas	
皮T-细胞淋巴瘤	335
16 Initiation and Control of Coagulation	
凝血的起动和控制	355
17 Transfusion: Blood and Blood Components	
输血:血液和血液成分	369
18 Hematologic and Neoplastic Aspects of Human Immunodeficiency Virus Infection	
HIV 感染有关的血液学和瘤形成问题	389
19 Autologous and Allogeneic Transplantation Procedures for Hematologic Malignancies	
血液恶性肿瘤的自体 and 异体移植过程	399
<b>Appendices 附录</b>	
A Normal Hematologic Parameters	
正常血液学参数	411
B Bone Marrow Differential Counts During Infancy and Childhood	
婴儿和儿童期骨髓分类计数	416
C Complement Activation	
补体活性	419
D Schilling Test: Interpretation of Excretion Values	
希林试验:排泄值的解释	420
E Hemoglobin-Oxygen Equilibrium Curve	
血红蛋白氧平衡曲线	421
F Osmotic Fragility of Erythrocytes	
红细胞渗透脆性	422
G Transitions in Myeloproliferative Disorders	
骨髓增生性疾病的过渡	425
H FAB Classifications	
白血病鉴别的法、美、英分类法	426
I Cytochemical Reactions in Normal and Abnormal Blood Cells	
正常和异常血细胞内细胞化学反应	430
J Cytochemical Reactions: Esterase	
细胞化学反应:酯酶	431
K Cytochemical Reactions in the Acute Leukemias (FAB Classification)	
急性白血病的细胞化学反应(法、美、英分类法)	432
L Platelet Organelles and Constituents	
血小板细胞器和成分	433
M Pathways of Blood Coagulation	
血液凝固途径	434
N Coagulation Schema as Previously Conceived	
以前设想的血液凝固图解	435
O Summary of Blood Components	
血液成分摘要	436
P Nomograms for Determining Body Surface Area	
体表面积测定计算图	441
Q Growth Factors and Hematopoietic Differentiation	
生长因子和造血作用鉴定	443
英汉索引	445

---

# 1. HEMATOPOIESIS AND HEMATOPOIETIC GROWTH FACTORS

---

Joseph J. Mazza

---

## Development of the Hematopoietic System

### *Embryonic Life*

1. Clusters of mesenchyme, mesodermal cells, on the yolk sac proliferate and expand during early embryonic life (about 2 weeks), forming the nidus of the embryonic and fetal hematopoietic system.

2. Vascular channels develop, allowing a connection to develop between the yolk sac and embryo, thus increasing the space available for further expansion of the mesodermal cells. In addition, the **primitive embryonic circulatory system** forms, and the endothelial cells derived from the early embryonic hematopoietic precursor cells become the lining cells of these primitive vascular channels.

3. **Proliferation** of the early hematopoietic cells occurs as the embryo grows and becomes a fetus (10–12 weeks). The development of a complex network of vascular channels connects vital organs and tissues, allowing for multiplication of the hematopoietic cells and perfusion by blood and lymph.

4. Differentiation of the hematopoietic precursor cells occurs in the immature reticuloendothelial system, which provides the unique microenvironment for proliferation and differentiation.

### *Fetal Hematopoiesis*

1. During early fetal life, after the tenth week of gestation, and through the entire second trimester of pregnancy, the **liver** and the **spleen** are the major sites for hematopoiesis.

2. As gestation continues into the third trimester, the sites of hematopoiesis gradually shift from the liver and spleen to the **medullary cavities of the bones**.

3. By birth, the medullary cavities of the bones are the major site of hematopoiesis, with virtually every bone contributing in this proliferative process and providing mature functional hematopoietic cells to the peripheral circulation.

4. **Pluripotential cells** remain in the other organs of the reticuloendothelial system as hematopoietic “rest cells.” These cells retain the potential to become sites of active hematopoiesis at any time later in life, thus giving rise to extramedullary hematopoiesis.


### *Hematopoietic Stem Cells*

Hematopoietic stem cells make up a unique clone of cells that are capable of differentiating into the multiple cell lines of hematopoietic system. Hematopoietic stem cells are believed to be present in all major organs that make up the reticuloendothelial system, as well as in the peripheral blood.

The stem cell clone must sustain itself by proliferation to continue its differentiation into the specialized hematopoietic cell lines. **Stem cell proliferation** is believed to be under direct influence of hematopoietic growth factors that are present in the local milieu of the reticuloendothelial system:

1. Proliferation and differentiation depend not only on growth factors (glycoprotein) but also on stromal cells and other cells that make up the unique microenvironment of the bone marrow.
2. If and when the uncommitted stem cell compartment has been depleted, hematopoiesis ceases. This may occur following exposure to ionizing radiation or high-dose chemotherapy.

Most **evidence for the existence** of these pluripotential stem cells comes from *in vitro* studies and animal models. Such studies have shown regenerative capabilities of the marrow and hematopoietic system after infusion of certain populations of mononuclear cells following complete hematopoietic ablation (Fig. 1)



**FIG. 1.** A model of hematopoietic stem cell differentiation. Illustrated are progenitor cells of increasingly restricted potentiality, which give rise to the maturing cells recognizable in bone marrow preparations as the immediate precursors of peripheral blood elements. BM, bone marrow; CFU, colony-forming unit; S, spleen; GEMM, granulocyte-erythrocyte-monocyte (or macrophage)-megakaryocyte; BFU, burst-forming-unit; EL, erythroid; GM, granulocyte-monocyte (or macrophage); EOS, eosinophil; BASO, basophil; MEG, megakaryocyte. (From Robinson SH. Hematopoiesis. In: Stein JH, ed. *Stein's internal medicine*, 3rd ed. Boston: Little, Brown and Company, 1990, with permission.)



1. Cultured stem cells on agar media grow and differentiate within 5 to 10 days, giving rise to colonies of hematopoietic cells.
2. Given a suspension of mononuclear bone marrow cells, lethally irradiated mice show hematopoietic proliferation in the marrow and spleen.

Only recently have these pluripotent stem cells been identified by surface markers through **cell membrane phenotyping** with monoclonal antibodies (Table 1). Morphologically, they are believed to be similar to large immature lymphocytes and to be diffusely distributed throughout the marrow.

A certain number of the uncommitted pluripotent stem cells will differentiate or become "committed" and give rise to the various myeloid and lymphoid cell lines, thus providing further proliferation and differentiation along the various specific myeloid and lymphoid cell lines.

In early childhood, the medullary cavities of virtually all bones are active sites of hematopoiesis. During adolescence and adulthood, the site of hematopoiesis gradually shifts from the long bones of the skeleton to the more central flat bones (i.e., the skull, vertebrae, ribs, sternum, and pelvis). These flat, more centrally located bones of the skeleton become the major sites of hematopoiesis in the adult.

### Kinetics of Hematopoietic Cells

Under normal conditions, all progenitor cells of the various cell lines undergo replication via the cell cycle (i.e., mitosis). Proliferation and differentiation are directly influenced and regulated by low-molecular-weight glycoproteins or hormones that are specific for each lineage of the hematopoietic system (see Appendix Q). These growth factors affect progenitor cells through specific membrane receptors, resulting in activation of the cell and replication and expansion of that precursor cell or lineage (see section entitled **Hematopoietic Growth Factors**). Many factors, in turn, regulate the production and elaboration of the necessary growth factors involved in hematopoiesis. This complex network of various hematopoietic growth factors and hormones, present in the local milieu of the marrow, is currently under careful, extensive investigation and has important therapeutic implications.

### Erythropoiesis

Various factors and mechanisms are involved in the regulatory process of production of the new erythrocytes to balance the rate of destruction. In the normal state, the balance of production and destruction is maintained at a remarkably constant rate. Both endocrine and exocrine hormones make important contributions to this dynamic, well-balanced mechanism (Table 2).

The **earliest recognizable erythroid precursor** seen in the bone marrow is a **large basophilic staining cell**, approximately 15 to 20  $\mu\text{m}$  in diameter, which contains a single large, well-defined, round nucleus; ribosomes; mitochondria; and Golgi apparatus (Table 1). As this early precursor cell matures, its nucleus becomes denser and smaller and eventually is extruded into the extracellular matrix of the bone marrow.

As maturation proceeds, the cell becomes progressively smaller and its cytoplasm more eosinophilic, representing increasing amounts of hemoglobin being synthesized from the ribosomes. During **intermediate stages of maturation**, the cytoplasm of the erythroblast is polychromatophilic, indicating the mixture of basophilic cytoplasmic proteins and the eosinophilic hemoglobin. With **further maturation**, hemoglobin synthesis continues, and the cytoplasm becomes entirely eosinophilic. In the **late stages of maturation**, hemoglobin is abundant. Few mitochondria and ribosomes are present in the cytoplasm; a small, dense, well-circumscribed nucleus is apparent.

When the nucleus is extruded, the cell becomes a **reticulocyte**, the last stage of development before it becomes a mature erythrocyte. Shortly thereafter, it acquires a biconcave external contour and specific properties of deformability and pliability. Its diameter is approximately 8 to 9  $\mu\text{m}$ . Most reticulocytes spend 1 to 2 days in the marrow undergoing further maturation before being released into the systemic circulation.

### Erythrokinetics

The **turnover rate of circulating erythrocytes** can be calculated easily because the number is constant under normal conditions and their circulating life span is

Table 1. Some immune cell antigens detected by monoclonal antibodies

Antigen designation	Comments
<b>Primary T cell associated</b>	
CD1	Expressed on cortical thymocytes and Langerhans histiocytes
CD2	Present on all T cells (thymic and peripheral) and NK cells
CD3	Expressed by thymocytes, peripheral T cells, and NK cells; surface expression requires coexpression of T-cell receptor
CD4	Expressed on the helper subset of peripheral T cells, single positive medullary thymocytes, and CD4/CD8 double positive thymocytes
CD5	Expressed on all T cells and small subset of B cells
CD6	Expressed on all T cells and subset of myeloid cell precursors
CD8	Expressed on the cytotoxic subset of peripheral T cells, single positive medullary thymocytes, double positive cortical thymocytes, and some NK cells
<b>Primary B cell associated</b>	
CD10	Expressed at high levels on marrow pre-B cells and follicular center B cells; also called CALLA
CD19	Present on marrow pre-B cells and mature B cells but not on plasma cells
CD20	Expressed on marrow pre-B cells after CD19 and mature B cells but not on plasma cells
CD21	EBV receptor; present on mature B cells and follicular dendritic cells
CD22	Present on mature B cells
CD23	Present on activated mature B cells
<b>Primarily monocyte or macrophage associated</b>	
CD13	Expressed on immature and mature monocytes and granulocytes
CD14	Expressed on all monocytes
CD15	Expressed on all granulocytes; also expressed by Reed-Sternberg cells and variants in Hodgkin disease
CD33	Expressed on myeloid progenitors and monocytes
CD117	Found on early myeloid precursors and myeloid leukemic clones
<b>Primarily NK cell associated</b>	
CD16	Present on all NK cells and granulocytes
CD56	Present on all NK cells and a subset of T cells
<b>Primarily stem cell and progenitor cell associated</b>	
CD34	Expressed on pluripotent hematopoietic stem cells and progenitor cells of many lineages
<b>Activation markers</b>	
CD30	Present on activated B cells, T cells, and monocytes
<b>Present on all leukocytes</b>	
CD45	Also known as leukocyte common antigen (LCA)
CD45RO	Expressed on activated memory T cells
CD45RA	Expressed on naïve T cells
<b>Miscellaneous</b>	
CD55	Defective in paroxysmal nocturnal hemoglobinuria;
CD59	
CD58	Present on all hematopoietic cells but not lineage specific;
CD40	Expressed on dendritic (antigen-presenting) cells
CD82	

CALLA, common acute lymphoblastic leukemia antigen; CD, cluster designation; EBV, Epstein-Barr virus; NK, natural killer.

Modified from Cotran RS, et al. *Robbins pathologic basis of disease*, 6th ed. Philadelphia: WB Saunders, 1999:654, with permission.